Equillium (EQ) Cash from Operations (2018 - 2026)
Equillium (EQ) posted quarterly Cash from Operations of 4301000.0 for Q1 2026, up 47.35% year-over-year from 2918905.79 in Q1 2025, and down 37.28% quarter-over-quarter from 3133000.0 in Q4 2025.
Equillium (EQ) Cash from Operations (2018 - 2026) Analysis & Trends
Equillium (EQ) has reported Cash from Operations for 9 consecutive years, with 4301000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 47.35% year-over-year to 4301000.0; the TTM figure through Mar 2026 stood at 18878000.0 (down 2.63% YoY), while the FY2025 annual figure was 22746000.0, down 19.55% from the prior year.
- Cash from Operations fell to 4301000.0 in Q1 2026 per EQ's latest filing, from 3133000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 27725000.0 in Q4 2022 and bottomed at 13065000.0 in Q3 2022.
- Historically, Cash from Operations has averaged 4505235.29 across 5 years, with a median of 6215000.0 in 2023.
- Annual changes were most pronounced in 2022 — Cash from Operations jumped 373.61% — and 2025, when it tumbled 512.74%.
- Equillium's Cash from Operations stood at 27725000.0 in 2022, then sank by 120.43% to 5664000.0 in 2023, then surged by 41.75% to 3299000.0 in 2024, then gained by 5.03% to 3133000.0 in 2025, then plunged by 37.28% to 4301000.0 in 2026.
- Business Quant data shows EQ's Cash from Operations at 4301000.0 in Q1 2026, 3133000.0 in Q4 2025, and 8431000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - | -4.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.11 Mn |
| Jun 30, 2026 | -4.11 Mn |
| Mar 31, 2026 | -4.30 Mn |
| Mar 31, 2026 | -4.30 Mn |
| Dec 31, 2025 | -3.13 Mn |
| Dec 31, 2025 | -3.13 Mn |
| Sep 30, 2025 | -8.43 Mn |
| Sep 30, 2025 | -8.43 Mn |
| Jun 30, 2025 | -3.01 Mn |
| Jun 30, 2025 | -3.01 Mn |
| Mar 31, 2025 | -8.17 Mn |
| Mar 31, 2025 | -8.17 Mn |
| Dec 31, 2024 | -3.30 Mn |
| Dec 31, 2024 | -3.30 Mn |
| Sep 30, 2024 | -7.66 Mn |
| Sep 30, 2024 | -7.66 Mn |
| Jun 30, 2024 | 730,000.00 |
| Jun 30, 2024 | 730,000.00 |
| Mar 31, 2024 | -8.80 Mn |
| Mar 31, 2024 | -8.80 Mn |